Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine in Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who, in the opinion of the investigator, can and will comply with the requirements of the protocol.~* A male or female between, and including, 18 and 50 years of age at the time of obtaining informed consent.~* Written (or thumb printed and witnessed) informed consent obtained from the subject.~* Baseline positive IGRA test result.~* Baseline negative HIV screen.~* Baseline negative clinical screening questionnaire and negative sputum sample for Pulmonary TB disease.~* Healthy subjects or those with chronic well-controlled disease as established by medical history and clinical examination.~* Female subjects of non-childbearing potential may be enrolled in the study.~  * Non-childbearing potential is defined as pre-menarche, current tubal ligation, hysterectomy, ovariectomy or post-menopause.~* Female subjects of childbearing potential may be enrolled in the study, if the subject:~  * has practiced adequate contraception for 25 days prior to vaccination, and~ * has a negative pregnancy test on the day of screening and the day of first vaccination, and~ * has agreed to continue adequate contraception during the entire vaccination period and for 2 months after completion of the vaccination series.~Exclusion Criteria:~* Current TB disease or history of TB disease and/or treatment for TB.~* Use of any investigational or non-registered product other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 30 days before and ending 30 days after each dose of vaccine.~* History of previous administration of experimental Mtb vaccines.~* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. Inhaled and topical steroids are allowed.~* Any condition or illness or medication, which in the opinion of the Investigator might interfere with the evaluation of the safety or immunogenicity of the vaccine.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.~* Planned participation or participation in another experimental protocol during the study.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.~* Administration of immunoglobulins and/or any blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period.~* History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines.~* History of medically confirmed autoimmune disease.~* Pregnant or lactating female.~* Female planning to become pregnant or planning to discontinue contraceptive precautions during the vaccination period and/or before 2 months after completion of the vaccination series.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- M72AS01 Group (Type: EXPERIMENTAL): Subjects, between, and including, 18 and 50 years of age, who received 2 doses of M72/AS01E according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm.
- Control group (Type: PLACEBO_COMPARATOR): Subjects, between, and including,18 and 50 years of age, who received 2 doses of Placebo according to random assignment, one month apart (Day 0 and Day 30) by intramuscular injection in the deltoid region of the arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).